NIMS Covid-19 Vaccination Centers
“Never run from the enemy, tackle them” Victoria Addino
The world is facing its biggest challenges in the history of mankind in the form of Covid-19. To date, the Novel Coronavirus has infected more than 17.5 Cr people worldwide, killing nearly 40 Lakh people. This looks like pretty much a lost battle unless we develop an effective vaccine and can vaccinate the masses, fast and safely. Thanks to the efforts of scientists and Govt. of India that we have received vaccine now and Nims Super-specialty Hospital is playing a major role in the drive, by running TWO Vaccination Centres as well as community camps...
Developing and Delivering the Vaccine:
Winning the invincible
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus causing coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, there was an established body of knowledge about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS), which enabled accelerated development of various vaccine technologies during early 2020. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to addressing COVID-19.
In Phase III trials, several COVID‑19 vaccines have demonstrated efficacy, as high as 95% in preventing symptomatic COVID‑19 infections. As of April 2021, 16 vaccines are authorized by at least one national regulatory authority for public use: three RNA vaccines (Pfizer–BioNTech and Moderna), seven conventional inactivated vaccines (BBIBP-CorV, CoronaVac, Covaxin, WIBP-CorV, CoviVac, Minhai-Kangtai and QazVac), five viral vector vaccines (Sputnik Light, Sputnik V, Oxford–AstraZeneca, Convidecia, and Johnson & Johnson), and two protein subunit vaccines (EpiVacCorona and RBD-Dimer).[failed verification] In total, as of March 2021, 308 vaccine candidates are in various stages of development, with 73 in clinical research, including 24 in Phase I trials, 33 in Phase I–II trials, and 16 in Phase III development.
Many countries have implemented phased distribution plans that prioritize those at the highest risk of complications, such as the elderly, and those at high risk of exposure and transmission, such as healthcare workers. Single-dose interim use is under consideration in order to extend vaccination to as many people as possible until vaccine availability improves.
As of 6 June 2021, 2.15 billion doses of the COVID‑19 vaccine have been administered worldwide based on official reports from national health agencies. AstraZeneca anticipates producing 3 billion doses in 2021, Pfizer–BioNTech 1.3 billion doses, and Sputnik V, Sinopharm, Sinovac, and Johnson & Johnson 1 billion doses each. Moderna targets producing 600 million doses and Convidecia 500 million doses in 2021. By December 2020, more than 10 billion vaccine doses had been preordered by countries, with about half of the doses purchased by high-income countries comprising 14% of the world's population.